4D Path Joins Phase II Clinical Trial to Advance Predictive Biomarkers in Bladder Cancer [Yahoo! Finance]
Gilead Sciences, Inc. (GILD)
Last gilead sciences, inc. earnings: 4/30 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investors.gilead.com
Company Research
Source: Yahoo! Finance
NEWTON, Mass., Jan. 22, 2026 (GLOBE NEWSWIRE) -- 4D Path , a company dedicated to personalizing cancer care through a novel, physics-inspired approach to predicting tumor response to therapy, today announced its participation as an exploratory biomarker collaborator in the Phase II DAD-IO clinical study (NCT04724018) led by Dana-Farber Cancer Institute and supported by Gilead Sciences, Inc. This high-profile study is evaluating a novel combination therapy for patients with locally advanced or metastatic urothelial carcinoma (mUC), including bladder cancer, and represents an important step forward in 4D Path's mission to redefine precision oncology. The DAD-IO study builds upon the successful Phase I Double Antibody Drug Conjugate (DAD) trial, examining a regimen that combines two powerful Antibody Drug Conjugates (ADC)—Sacituzumab Govitecan (SG, from Gilead) and Enfortumab Vedotin (EV, from Seagen/Astellas)—with or without the immune checkpoint inhibitor Pembrolizumab. This approac
Show less
Read more
Impact Snapshot
Event Time:
GILD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
GILD alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
GILD alerts
High impacting Gilead Sciences, Inc. news events
Weekly update
A roundup of the hottest topics
GILD
News
- FDA Approves Label Update for Kite’s Yescarta® for Relapsed/Refractory Primary Central Nervous System LymphomaBusiness Wire
- Is Gilead Sciences (GILD) Still Attractive After Strong Multi-Year Share Price Gains [Yahoo! Finance]Yahoo! Finance
- GSK's oncology and HIV drugs drive 7% sales rise in 2025 [Yahoo! Finance]Yahoo! Finance
- Gilead Sciences, Inc. (GILD): A Bull Case Theory [Yahoo! Finance]Yahoo! Finance
- Truist Securities Raises Price Target on Gilead Sciences, Inc. (GILD) to $145, Keeps Buy Rating [Yahoo! Finance]Yahoo! Finance
GILD
Earnings
- 10/30/25 - Beat
GILD
Sec Filings
- 2/5/26 - Form 4
- 2/5/26 - Form 4
- 2/5/26 - Form 4
- GILD's page on the SEC website